PubRank

A Study to Evaluate the Effects of a Turmeric and Black Cumin Seed Formulation on Cholesterol Levels

Clinical Trial ID NCT03175757

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03175757

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001 5.78
2 Pharmacological and toxicological properties of Nigella sativa. Phytother Res 2003 2.78
3 Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001 2.69
4 Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 2011 2.62
5 Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging 2014 1.69
6 Effect of thymoquinone and Nigella sativa seeds oil on lipid peroxidation level during global cerebral ischemia-reperfusion injury in rat hippocampus. Phytomedicine 2007 1.52
7 Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem 2006 1.23
8 Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors 2013 1.10
9 The effect of thymoquinone on blood lipids in rats. Indian J Physiol Pharmacol 2002 1.04
10 Effects of Nigella sativa fixed oil on blood homeostasis in rat. J Ethnopharmacol 2002 1.03
11 Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis. Mol Nutr Food Res 2012 0.89
12 Toxicity effect of nigella sativa on the liver function of rats. Adv Pharm Bull 2013 0.89
13 Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res 2013 0.88
14 Effect of Nigella sativa (kalonji) on serum cholesterol of albino rats. J Ayub Med Coll Abbottabad 2005 0.84
15 Nigella sativa: A Potential Antiosteoporotic Agent. Evid Based Complement Alternat Med 2012 0.82
16 Favorable impact of Nigella sativa seeds on lipid profile in type 2 diabetic patients. J Family Community Med 2012 0.82
17 Curcumin promotes cholesterol efflux from adipocytes related to PPARgamma-LXRalpha-ABCA1 passway. Mol Cell Biochem 2011 0.81
18 Cardio-protective and anti-cancer therapeutic potential of Nigella sativa. Iran J Basic Med Sci 2014 0.81
19 Curcuma oil ameliorates hyperlipidaemia and associated deleterious effects in golden Syrian hamsters. Br J Nutr 2013 0.81
20 Protective Effects of Nigella sativa on Metabolic Syndrome in Menopausal Women. Adv Pharm Bull 2013 0.81
21 Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Mol Nutr Food Res 2014 0.81
22 Hypolipidemic and antioxidant activities of thymoquinone and limonene in atherogenic suspension fed rats. Food Chem 2012 0.80
23 Curcumin inhibits monocyte chemoattractant protein-1 expression and enhances cholesterol efflux by suppressing the c-Jun N-terminal kinase pathway in macrophage. Inflamm Res 2014 0.79
24 The Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial. Iran J Pharm Res 2015 0.79
25 Regulation of LDL receptor expression by the effect of curcumin on sterol regulatory element pathway. Pharmacol Rep 2006 0.79
26 Curcuma oil attenuates accelerated atherosclerosis and macrophage foam-cell formation by modulating genes involved in plaque stability, lipid homeostasis and inflammation. Br J Nutr 2014 0.78
27 Antiatherogenic Potential of Nigella sativa Seeds and Oil in Diet-Induced Hypercholesterolemia in Rabbits. Evid Based Complement Alternat Med 2011 0.78
28 Curcumin enhanced cholesterol efflux by upregulating ABCA1 expression through AMPK-SIRT1-LXRα signaling in THP-1 macrophage-derived foam cells. DNA Cell Biol 2015 0.78
29 Nigella sativa (black seed) effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res 2016 0.78
30 Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. J Cardiovasc Pharmacol 2016 0.77
31 Ameliorative effects of Nigella sativa on dyslipidemia. J Endocrinol Invest 2015 0.77
32 Curcumin retunes cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent atherosclerosis. Biochem Biophys Res Commun 2015 0.77
33 Clinical efficacy of the co-administration of Turmeric and Black seeds (Kalongi) in metabolic syndrome - a double blind randomized controlled trial - TAK-MetS trial. Complement Ther Med 2015 0.77
34 Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. Nutrition 2016 0.76
35 The effect of nutritional supplements on serum high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiovasc Drugs 2014 0.76
36 Coadministration of black seeds and turmeric shows enhanced efficacy in preventing metabolic syndrome in fructose-fed rats. J Cardiovasc Pharmacol 2015 0.76
37 Attenuation of the development of hypercholesterolemic atherosclerosis by thymoquinone. Int J Angiol 2008 0.75
38 Curcumin Supplementation Decreases Intestinal Adiposity Accumulation, Serum Cholesterol Alterations, and Oxidative Stress in Ovariectomized Rats. Oxid Med Cell Longev 2015 0.75
39 Effects of black seed (Nigella sativa) on metabolic parameters in diabetes mellitus: a systematic review. Complement Ther Med 2015 0.75
40 Induction of apolipoprotein A-I gene expression by black seed (Nigella sativa) extracts. Pharm Biol 2014 0.75
41 Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res 2014 0.75
Next 100